You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

382 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - In Combination with Pomalidomide and Dexamethasone for Previously Treated Multiple Myeloma
ODB - General Benefit
    dexamethasone
Exceptional Access Program
    pomalidomide - For patients with relapsed and/or refractory multiple myeloma, according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
bortezomib,
dexamethasone,
pomalidomide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2025
Drug
Other Name(s): Velcade®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Nov 2024
Drug
Other Name(s): Neupogen®, Grastofil®, Nivestym®, Nypozi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Updated
Apr 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
daratumumab (Unfunded),
bortezomib (Unfunded),
lenalidomide (Unfunded),
dexamethasone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Updated
Apr 2025
Document
New
Apr 2025
Document
New
Apr 2025
Document
New
Apr 2025
Document
New
Apr 2025
Document
New
Apr 2025
Document
New
Apr 2025
Document
New
Apr 2025

Pages